In 5 to 20% of patients’ resistance to EGFR treatment was associated with MET amplification, as was reported for therapy in CRC with antibodies [35] and in NSCLC for the kinase inhibitors erlotinib and gefitinib [36]. Here, EGFR is linked to non-small cell lung carcinoma.